Previous 10 | Next 10 |
2023-08-24 19:15:17 ET More on Biogen Biogen Q2 2023 Analysis: Reata Acquisition, Financials, And Alzheimer's Prospects Biogen Inc. ( BIIB ) Q2 2023 Earnings Call Transcript Biogen And Alzheimer's Disease: Too Early To Celebrate Will Watershed Moment For ...
2023-08-24 09:44:18 ET The Biden administration is expected to announce the first 10 drugs that will be subject to Medicare price negotiations on Tuesday before the markets open, Politico reported, citing people familiar with the plans. The move, introduced as part of last year ...
2023-08-24 02:20:26 ET Summary Bristol-Myers has a strong history of investment outperformance during equity bear markets and recessions. The company is uniquely undervalued, with a low 8x P/E and nearly 4% cash dividend yield. After a weak first half of 2023, shares may rebou...
2023-08-23 14:09:18 ET More on Biogen Biogen And Alzheimer's Disease: Too Early To Celebrate Will Watershed Moment For Alzheimer's Propel Biogen Stock Higher? Seeking Alpha’s Quant Rating on Biogen For further details see: Biogen's Leqembi set for ...
2023-08-16 14:13:34 ET BofA Securities has upgraded Axsome Therapeutics ( NASDAQ: AXSM ) to neutral, citing an improved outlook for the company's drug Auvelity for major depressive disorder, or MDD. The investment bank said it was upgrading the stock primarily because Axsome's M...
2023-08-16 11:59:12 ET More on GE HealthCare Technologies GE HealthCare: Good Growth Prospects At A Reasonable Valuation GE HealthCare Technologies: Q2 2023 Earnings Solidify Bullish Case GE HealthCare Technologies Inc. ( GEHC ) Q2 2023 Earnings Call Transcript...
2023-08-15 16:20:35 ET More on Reata Pharmaceuticals Biogen's Bold $7.3B Acquisition Of Reata: Analyzing The Impact On Investors Reata: FDA Approval Of SKYCLARYS Isn't Only Driver Moving Forward Reata Pharmaceuticals: 'Buy' Following Skyclarys Delay And Bardoxolone D...
2023-08-14 16:38:10 ET Summary Sage Therapeutics, Inc. has a virtual monopoly in treating postpartum depression, a condition that affects 15%-20% of postpartum women. The company's pipeline focuses on treating CNS disorders by modulating GABA and NMDA receptors. The major depr...
2023-08-14 07:00:00 ET Summary Biotech stocks faced challenges in the first half of the year, with the Nasdaq Biotechnology Index losing 3%, compared to strong advances in the broader market. The direction of the 10-year bond yield has become a key predictor of biotech industry pe...
2023-08-14 05:45:30 ET Summary Coya Therapeutics is developing Treg-enhancing therapeutics to target diseases driven by inflammation, including in the central nervous system, including ALS. Coya Therapeutics' ALS drug could be approved based on pivotal phase 2 results and could po...
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has completed the acquisition of Human Immunology Biosciences (HI-Bio™), a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases ...
TOKYO and CAMBRIDGE, Mass., June 27, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today tha...
NEW YORK, NY / ACCESSWIRE / June 12, 2024 / Leading law firm Bleichmar Fonti & Auld LLP announces the upcoming July 22, 2024, deadline in the Biogen Inc. (Nasdaq:BIIB) Securities Class Action Lawsuit. If you invested in Biogen, you are encouraged to obtain additional information by visiting ...